InsiderTrades

Form 4 for ASPI ASP Isotopes Inc.

Accepted 2026-04-17 21:54:03 ET · period of report 2025-11-12 · accession 0001477932-26-002387 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MT 2026-04-17 21:54 2025-11-12+ ASPI Moore Duncan Dir A - Grant — +62.0K 1.06M +6% —
T 2026-04-17 21:54 2026-04-16 ASPI Moore Duncan Dir S - Sale $5.21 -11.6K 1.04M -1% -$60.6K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-11-12 A A 25,469 — 1,020,022 D — — (F1) Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee.
2 Common Common Stock 2025-12-18 A A 36,548 — 1,056,570 D — — (F2) 2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc.
3 Common Common Stock 2026-04-16 S D 11,642 $5.21 1,044,928 D — — (F3) The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2.